Basophil activation test: A diagnostic, predictive and monitoring assay for allergen immunotherapy

For decades, the approach to clinical care has involved the assessment of a fairly small set of patients' signs and symptoms, sampled over a short period of time with limited attention given to individual variations in aetiology and pathophysiology. Subsequently, a therapy is assigned predomina...

Full description

Saved in:
Bibliographic Details
Published in:Allergy (Copenhagen) 2021-05, Vol.76 (5), p.1321-1324
Main Authors: Alpan, Oral, Layhadi, Janice A., Ulrik Sønder, Søren, Li, Henry, Shamji, Mohamed H.
Format: Article
Language:English
Subjects:
Allergens
Allergies
allergy treatment
basophil
Biomarkers
immunological tests
Immunotherapy
immunotherapy and tolerance induction
immunotherapy clinical
Medical diagnosis
Monoclonal antibodies
Precision medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For decades, the approach to clinical care has involved the assessment of a fairly small set of patients' signs and symptoms, sampled over a short period of time with limited attention given to individual variations in aetiology and pathophysiology. Subsequently, a therapy is assigned predominantly with a "one shoe fits all" approach. Precision medicine approaches are now starting to change ways to test, treat and develop new therapies for allergic and immunological disorders (Figure 1)... Despite the success story in biomarker‐driven treatment selection with Herceptin, there has been a significant gap in the development of such companion diagnostics in other indications, partly due to the difficulties in either identifying or not knowing the signals that induce biomarkers relevant for predicting treatment outcomes. To tackle this gap for allergic patients, Hoffmann et al2 now introduce “Time” as a 3rd dimension, to static and induced biomarkers. They elegantly show, using a functional basophil assay, how changes over a short period of 3 weeks after initiation of therapy can predict long‐term clinical outcomes following subcutaneous immunotherapy (SCIT).
ISSN:0105-4538
1398-9995
DOI:10.1111/all.14585